Goldman Sachs Group, Inc. (The) Reaffirms Buy Rating for Sarepta Therapeutics, Inc. (SRPT)

Goldman Sachs Group, Inc. (The) reissued their buy rating on shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in a research note released on Friday morning, MarketBeat reports. They currently have a $71.00 target price on the biotechnology company’s stock.

Other equities research analysts also recently issued research reports about the company. SunTrust Banks, Inc. reissued a buy rating on shares of Sarepta Therapeutics in a report on Thursday, July 20th. Credit Suisse Group set a $64.00 target price on Sarepta Therapeutics and gave the stock a buy rating in a report on Tuesday, July 18th. Leerink Swann reissued a buy rating and set a $60.00 target price (up previously from $52.00) on shares of Sarepta Therapeutics in a report on Tuesday, July 18th. BidaskClub raised Sarepta Therapeutics from a hold rating to a buy rating in a report on Friday, June 23rd. Finally, Royal Bank Of Canada reissued a buy rating and set a $60.00 target price on shares of Sarepta Therapeutics in a report on Thursday, June 22nd. One analyst has rated the stock with a sell rating, seven have issued a hold rating and sixteen have assigned a buy rating to the company’s stock. Sarepta Therapeutics presently has a consensus rating of Buy and an average price target of $64.34.

Shares of Sarepta Therapeutics (NASDAQ SRPT) opened at 51.26 on Friday. Sarepta Therapeutics has a one year low of $26.26 and a one year high of $57.35. The firm has a 50-day moving average of $44.02 and a 200 day moving average of $36.58. The company’s market cap is $3.30 billion.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.92) by $0.46. The firm had revenue of $35.01 million for the quarter, compared to analyst estimates of $22.52 million. During the same period in the prior year, the business posted ($1.19) EPS. The firm’s quarterly revenue was up 350000.0% compared to the same quarter last year. Equities research analysts anticipate that Sarepta Therapeutics will post ($1.16) EPS for the current year.

TRADEMARK VIOLATION WARNING: This report was originally posted by BBNS and is the sole property of of BBNS. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at https://baseballnewssource.com/markets/goldman-sachs-group-inc-the-reaffirms-buy-rating-for-sarepta-therapeutics-inc-srpt/1703013.html.

In other news, SVP Shamim Ruff sold 12,138 shares of the business’s stock in a transaction dated Friday, July 21st. The stock was sold at an average price of $42.97, for a total transaction of $521,569.86. Following the sale, the senior vice president now directly owns 27,312 shares in the company, valued at $1,173,596.64. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Alexander Cumbo sold 5,918 shares of the business’s stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $41.00, for a total value of $242,638.00. Following the sale, the senior vice president now owns 22,793 shares in the company, valued at $934,513. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 89,556 shares of company stock worth $3,799,208. Company insiders own 9.60% of the company’s stock.

Several large investors have recently added to or reduced their stakes in SRPT. Russell Investments Group Ltd. grew its holdings in shares of Sarepta Therapeutics by 63.9% during the first quarter. Russell Investments Group Ltd. now owns 38,273 shares of the biotechnology company’s stock worth $1,133,000 after purchasing an additional 14,919 shares during the last quarter. Wells Fargo & Company MN grew its holdings in shares of Sarepta Therapeutics by 24.4% during the first quarter. Wells Fargo & Company MN now owns 84,710 shares of the biotechnology company’s stock worth $2,508,000 after purchasing an additional 16,620 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Sarepta Therapeutics by 0.8% during the first quarter. Bank of New York Mellon Corp now owns 247,924 shares of the biotechnology company’s stock worth $7,339,000 after purchasing an additional 1,923 shares during the last quarter. Swiss National Bank grew its holdings in shares of Sarepta Therapeutics by 3.9% during the first quarter. Swiss National Bank now owns 85,400 shares of the biotechnology company’s stock worth $2,528,000 after purchasing an additional 3,200 shares during the last quarter. Finally, Ameriprise Financial Inc. grew its holdings in shares of Sarepta Therapeutics by 117.2% during the first quarter. Ameriprise Financial Inc. now owns 33,908 shares of the biotechnology company’s stock worth $544,000 after purchasing an additional 18,297 shares during the last quarter. Institutional investors own 65.41% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Aaron Judge and Gary Sanchez Have Break Out Games
Aaron Judge and Gary Sanchez Have Break Out Games
Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Red Sox Waste Little Time in Firing John Farrell
Red Sox Waste Little Time in Firing John Farrell
Washington Nationals Sans Strasburg for Game 4 at Wrigley
Washington Nationals Sans Strasburg for Game 4 at Wrigley


Leave a Reply

 
© 2006-2017 BBNS.